

## Working Group on Interventional Treatment of Hypertension

### Steering Committee

**Chairman:** Roland Schmieder [roland.schmieder@fau.de](mailto:roland.schmieder@fau.de)

**Vice –Chairman:** Felix Mahfoud – [felix.mahfoud@uks.eu](mailto:felix.mahfoud@uks.eu)

**Secretary:** Kyriakos Dimitriadis – [dimitriadiskyr@yahoo.gr](mailto:dimitriadiskyr@yahoo.gr)

### Nucleous:

Bram Kroon [aa.kroon@mumc.nl](mailto:aa.kroon@mumc.nl)

Filippo Scalise [filippo.scalise@policlinicodimonza.it](mailto:filippo.scalise@policlinicodimonza.it)

Christian Ott - [christian.ott@klinikum-nuernberg.de](mailto:christian.ott@klinikum-nuernberg.de)

### Members

R. Schmieder	<a href="mailto:roland.schmieder@fau.de">roland.schmieder@fau.de</a>
K. Tsioufis	<a href="mailto:ktsioufis@gmail.com">ktsioufis@gmail.com</a>
J. Redon	<a href="mailto:josep.redon@uv.es">josep.redon@uv.es</a>
G. Mancia	<a href="mailto:giuseppe.mancia@unimib.it">giuseppe.mancia@unimib.it</a>
G. Grassi	<a href="mailto:guido.grassi@unimib.it">guido.grassi@unimib.it</a>
M. Burnier	<a href="mailto:michel.burnier@chuv.ch">michel.burnier@chuv.ch</a>
P. Van de Borne	<a href="mailto:philippe.van.de.borne@erasme.ulb.ac.be">philippe.van.de.borne@erasme.ulb.ac.be</a>
S. Kjeldsen	<a href="mailto:sverrkj@online.no">sverrkj@online.no</a>
K. Narkiewicz	<a href="mailto:knark@gumed.edu.pl">knark@gumed.edu.pl</a>
G. Parati	<a href="mailto:gianfranco.parati@unimib.it">gianfranco.parati@unimib.it</a>
T. Kahan	<a href="mailto:thomas.kahan@ds.se">thomas.kahan@ds.se</a>
D. Vlachakos	?
C. Thomopoulos	<a href="mailto:thokos@otenet.gr">thokos@otenet.gr</a>
D. Tsiachris	<a href="mailto:dtsiachris@yahoo.com">dtsiachris@yahoo.com</a>
K. Dimitriadis	<a href="mailto:dimitriadiskyr@yahoo.gr">dimitriadiskyr@yahoo.gr</a>
A. Manolis	<a href="mailto:ajmanol@otenet.gr">ajmanol@otenet.gr</a>
L. Ruilope	<a href="mailto:ruilope@ad0hocbox.com">ruilope@ad0hocbox.com</a>
P.W. de Leeuw	<a href="mailto:p.deleeuw@maastrichtuniversity.nl">p.deleeuw@maastrichtuniversity.nl</a>
M. Doumas	<a href="mailto:michalisdoumas@yahoo.co.uk">michalisdoumas@yahoo.co.uk</a>
M. Viigimaa	<a href="mailto:margus.viigimaa@regionaalhaigla.ee">margus.viigimaa@regionaalhaigla.ee</a>
R. Veelken	<a href="mailto:roland.veelken@klinikum-nuernberg.de">roland.veelken@klinikum-nuernberg.de</a>
F. Mahfoud	<a href="mailto:felix.mahfoud@uks.eu">felix.mahfoud@uks.eu</a>
G. Seravalle	<a href="mailto:g_seravalle@yahoo.com">g_seravalle@yahoo.com</a>
C. Ott	<a href="mailto:christian.ott@ukOerlangen.de">christian.ott@ukOerlangen.de</a>
R. Santamaría	<a href="mailto:rsantamario@gmail.com">rsantamario@gmail.com</a>
S. Nadeida	<a href="mailto:saponic_nadia@yahoo.com">saponic_nadia@yahoo.com</a>
P. Araújo Gonçalves	<a href="mailto:paraujogoncalves@yahoo.co.uk">paraujogoncalves@yahoo.co.uk</a>
M. Almeida	<a href="mailto:allmeidams@sapo.pt">allmeidams@sapo.pt</a>
P. Branco	<a href="mailto:mateus.meg@gmail.com">mateus.meg@gmail.com</a>
T. Yaneva	<a href="mailto:teodora.yaneva@gmail.com">teodora.yaneva@gmail.com</a>
F. Scalise	<a href="mailto:filippo.scalise@policlinicodimonza.it">filippo.scalise@policlinicodimonza.it</a>
A. Kroon	<a href="mailto:aa.kroon@mumc.nl">aa.kroon@mumc.nl</a>
Wilko Spiering	<a href="mailto:W.Spiering@umcutrecht.nl">W.Spiering@umcutrecht.nl</a>
Melvin Lobo	<a href="mailto:m.d.lobo@qmul.ac.uk">m.d.lobo@qmul.ac.uk</a>
Atul Pathak	<a href="mailto:apathak@clinique-pasteur.com">apathak@clinique-pasteur.com</a>
Markus Schlaich	<a href="mailto:Markus.Schlaich@uwa.edu.au">Markus Schlaich &lt;markus.schlaich@uwa.edu.au&gt;</a>

Hypertension remains the first cause of cardiovascular morbidity and mortality and despite the use of effective antihypertensive drugs0even in combinations0 a significant portion remains uncontrolled. Nowadays, there is compelling need to focus on novel therapeutic modalities based on percutaneous renal sympathetic denervation and implantable baroreflex modifying devices for improving blood pressure control in essential hypertensive patients and ameliorating concomitant cardiovascular risk factors as well as in transcutaneous treatment of renovascular hypertension.

Based on the above, the **WG "INTERVENTIONAL TREATMENT OF HYPERTENSION "** will focus at least on the following three subjects:

1. renal nerve ablation
2. baroreflex activation
3. renal artery stenosis (dilation, stenting)

The Working Group "Interventional Treatment of Hypertension" serves as a forum of discussion, debate and exchange of scientific knowledge and clinical experience in the emerging field of interventional treatment of hypertension. The collaboration of scientists working in this field through the Working Group "Interventional Treatment of Hypertension" would leverage past experience and help to set visionary and achievable future goals towards better treatment of hypertension.

**Aims: The WG would mainly focus on:**

1. Educating cardiologists, nephrologists, radiologists, pathologists, GPs and other medical specialities with special interest in hypertension in addressing the challenges of interventional therapy of patients with hypertension
2. Facilitating communication and collaboration among doctors and researchers
3. Translating basic and applied research into effective interventional treatment strategies
4. Informing the medical community of current scientific knowledge in hypertension management by current interventional treatments
5. Promoting communication with other working groups and societies in the field
6. Improving the organization and scientific content of teaching seminars and tutorials

**Activities**

1. Deliver recommendations for optimal interventional treatment of hypertension.
2. Organize International Symposia under the auspices of the ESH in order to further communicate the advances in interventional approach to hypertension therapy.
3. Leading a certification process within the ESH for those involved in interventional hypertension therapy.
4. Initiate and organize registries in order to promote understanding, to address current problems in interventional approach and to improve the therapies provided to patients.
5. New website project to foster the creation of the WG and its activities.
6. Participation in international scientific congresses and publication of papers, reviews, editorials, case reports and letters.

7. Provide information to the community and patients on the recent advances in hypertension interventional treatment.

**Applicants should have:**

- A degree in medicine and/or specialization in cardiology, nephrology, internal medicine or any biomedical science
- A position in a medical/scientific institution
- An ongoing scientific activity (according to main publications and impact factor)
- A willingness to actively participate in Working Group activities (list of fields of interest)

Last activities:

During the ESH 2018 in Barcelona:

- Working Group Meeting
- Working Group Symposium  
Title: Focus on Renal Denervation 2018

- ESH WG Statement:

“The long path from prediction before the experimental verification of the BP lowering effect of RDN: a tribute to all the pioneers in this research field” in preparation.